Catalyst Biosciences (CBIO) Announces Earnings Results

Share on StockTwits

Catalyst Biosciences (NASDAQ:CBIO) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.26) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.08) by ($0.18), Bloomberg Earnings reports.

Shares of Catalyst Biosciences stock traded up $0.21 on Friday, reaching $8.41. The company’s stock had a trading volume of 7,861 shares, compared to its average volume of 213,754. The stock has a market capitalization of $104.18 million, a PE ratio of -3.14 and a beta of 2.46. Catalyst Biosciences has a 52-week low of $6.20 and a 52-week high of $29.95.

CBIO has been the subject of a number of analyst reports. CIBC initiated coverage on Catalyst Biosciences in a report on Friday, January 4th. They issued an “outperform” rating and a $24.00 price target for the company. Zacks Investment Research downgraded Catalyst Biosciences from a “hold” rating to a “sell” rating in a report on Tuesday, March 12th. Finally, Oppenheimer started coverage on Catalyst Biosciences in a report on Friday, January 4th. They issued an “outperform” rating and a $24.00 price target for the company. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $21.50.

A hedge fund recently raised its stake in Catalyst Biosciences stock. Geode Capital Management LLC grew its holdings in Catalyst Biosciences Inc (NASDAQ:CBIO) by 3.9% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 144,175 shares of the biopharmaceutical company’s stock after buying an additional 5,405 shares during the quarter. Geode Capital Management LLC owned 1.21% of Catalyst Biosciences worth $1,137,000 as of its most recent SEC filing. Institutional investors and hedge funds own 62.55% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Catalyst Biosciences (CBIO) Announces Earnings Results” was originally reported by Week Herald and is owned by of Week Herald. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at

About Catalyst Biosciences

Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.

Featured Article: Moving Average (MA)

Earnings History for Catalyst Biosciences (NASDAQ:CBIO)

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with's FREE daily email newsletter.